Text Size

A Clinical Trial of Acamprosate for Treatment of Methamphetamine Addiction (AcampMet)

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by:
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00571922
First received: December 10, 2007
Last updated: June 3, 2011
Last verified: June 2011
History of Changes
  Purpose

This clinical trial will compare 10 week treatment with acamprosate (2 gr/day) versus placebo, combined with weekly abstinence oriented individual counseling, in methamphetamine dependent patients, 72 subjects will be enrolled, with an interim analysis scheduled after 36 enrolled. Primary ouitcome is methamphetamine nabsitience over the 10 week treatment period, and the last 2 weeks of treatment. Abstinence is defined on a weekly basis as no urines positive of methamphetamine (or amphetamine) and self-report of not use for the 7 day period. Secondary measures include treatment retention, drug craving, mood, and safety.


Condition Intervention Phase
Methamphetamine Dependence, Treatment Seeking
 Drug: Acamprosate
Drug: placebo
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Placebo-controlled, Double Blind, Randomized Trial of Acamprosate for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine
U.S. FDA Resources

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • methamphetamine abstinence [ Time Frame: 7 day ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • craving [ Time Frame: 7 day ] [ Designated as safety issue: No ]

Estimated Enrollment: 72
Study Start Date: July 2007
Arms Assigned Interventions
Active Comparator: 1
Acamprosate
 Drug: Acamprosate
2 gr/day (333 mg, TID)
Other Name: Campral
Placebo Comparator: 2
placebo medication
 Drug: placebo
matching placebo
Other Name: placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Methamphetamine dependence
  • Treatment seeking
  • Urine sample (+) for methmamphetamine

Exclusion Criteria:

  • Pregnancy
  • Dependence on other drugs (except nicotine)
  • DSM-IV axis I disorder unrelated to drug abuse
  • Serious medical condition in clinicians opinion.
  • AIDs
  • Untreated syphyilis
  • Allergy to acamprosate
  • Methadone, or other ORP, maintenence
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00571922

Locations
United States, New York
VA New York Harbor Healthcare System, MHAD clinic
New York, New York, United States, 10010
Sponsors and Collaborators
New York University School of Medicine
Forest Laboratories
Investigators
Principal Investigator: Malcolm Reid, PhD New York University School of Medicine
  More Information

No publications provided

Responsible Party: Malcolm S. Reid, Assistant Professor, New York University School of Medicine, Department of Psychiatry
ClinicalTrials.gov Identifier: NCT00571922     History of Changes
Other Study ID Numbers: AcamprosateMethamphetamine, CMP-MD-17
Study First Received: December 10, 2007
Last Updated: June 3, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by New York University School of Medicine:
methamphetamine, crystal, treatment

Additional relevant MeSH terms:
Methamphetamine
Amphetamine
Acamprosate
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents
Neurotransmitter Agents
 Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors
Alcohol Deterrents

ClinicalTrials.gov processed this record on May 19, 2013